Xencor, Inc. (NASDAQ:XNCR) Receives $33.86 Average PT from Analysts

Xencor, Inc. (NASDAQ:XNCR) has received a consensus recommendation of “Buy” from the eight brokerages that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $33.86.

XNCR has been the topic of a number of recent research reports. Wells Fargo & Company dropped their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. William Blair began coverage on Xencor in a report on Monday. They issued an “outperform” rating on the stock. Finally, StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th.

Institutional Trading of Xencor

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XNCR. Sterling Capital Management LLC raised its stake in shares of Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,040 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Xencor in the 4th quarter worth about $34,000. GAMMA Investing LLC boosted its stake in Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 508 shares during the period. KBC Group NV boosted its position in Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 813 shares during the period. Finally, PNC Financial Services Group Inc. grew its position in shares of Xencor by 49.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock worth $93,000 after acquiring an additional 1,337 shares during the last quarter.

Xencor Stock Up 9.3 %

Shares of NASDAQ XNCR opened at $10.60 on Friday. The company has a market capitalization of $746.90 million, a price-to-earnings ratio of -3.31 and a beta of 0.90. Xencor has a 1 year low of $7.16 and a 1 year high of $27.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The business has a 50-day moving average of $12.21 and a two-hundred day moving average of $18.66.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. On average, analysts forecast that Xencor will post -3.68 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.